Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Cybin | History Defined

The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics

The agency issued "national priority vouchers" for the two drugs six days after President Donald Trump promised to facilitate approval of psychedelic therapies.

Reason

Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.

Benzinga

Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression

Cybin Inc.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S.

Benzinga

How Does Ketamine Affect The Brain Over Time?

This article was originally published on Cannabis & Tech Today and appears here with permission. Cannabis legalization is opening the floodgates for alternative medicines. Ketamine in particular is showing promise and one company is taking a novel approach to researching the drug.

Benzinga

Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.

Benzinga

Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder

Cybin Inc.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin

Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp.

Benzinga

Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog

Cybin Inc. (CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics," has submitted an Investigational New Drug (or “IND”) application to the FDA.

Benzinga

Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today

GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 16.85% at $0.32

Benzinga

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs

Psychedelics policy action took center stage this week.

Benzinga

Pilot Study By Cybin Shows That Ketamine Modifies Connectivity Between Brain Regions

Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March,&nbs

Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Benzinga

Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to it

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.

Benzinga

Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics

CYB004 is one of Cybin’s (NYSE:CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and substance abuse disorders. According to the company, the substance has recently shown positive preclinical data over DMT, the molecule from which it is derived. Cybin has observed that the preclinical study showed promising results for…

Benzinga

WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies

Cybin Inc. (NYSE:CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules. “Our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation,…

Benzinga

Is The UK Becoming A Global Center For Psychedelic Medicine?

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research isn’t enough to convince you, then two more crucial factors surely will. Firstly, a new ‘accelerated pathway’ has…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE:CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,” he said in an interview, explaining his…

Benzinga

Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin Inc. (NYSE:CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without the need for a more expensive and oversized piece of equipment, Kernal Flow…

Benzinga

Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder

Cybin Inc. (NYSE:CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. The goal is to analyze the potential of the compound in treating major depressive disorder (MDD). The studies were carried out on multiple species and included several doses of the substance, which were reportedly…

Benzinga

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Benzinga

Psychedelic Stock Gainers And Losers From March 1, 2022

GAINERS: Cybin (AMEX:CYBN) shares closed up 4.25% at $0.94

Benzinga

EXCLUSIVE: How This Company Backed By Deepak Chopra & Tony Robbins Is Disrupting Mental Health With Psychedelics

Doug Drysdale, CEO of Cybin Inc. (NYSE: CYBN) recently joined Javier Hasse and Elliot Lane on the Benzinga Cannabis Insider show.

Benzinga

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. A new Johns Hopkins review study found that the positive effects of just two sessions of psilocybin-assisted psychotherapy can last for over one year in most patients with…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.